O8 Use of therapeutic strategies with cardiovascular benefit in a population of patients with type 2 diabetes in follow up by cardiologist

Authors

  • Augusto Lavalle Cobo Argentine Society of Cardiology, Autonomous City of Buenos Aires, Argentina
  • Paola Harwicz Argentine Society of Cardiology, Autonomous City of Buenos Aires, Argentina
  • Carlos Busso Argentine Society of Cardiology, Autonomous City of Buenos Aires, Argentina
  • Julio Napoli Institute of Diagnosis and Medical Research Formosa, Formosa, Argentina
  • Hugo Sanabria Argentine Society of Cardiology, Autonomous City of Buenos Aires, Argentina
  • Carolina Gómez Martín CENDIA Diabetes Center, Concordia, Entre Ríos, Argentina
  • Alfredo Romano Institute of Diagnosis and Medical Research Formosa, Formosa, Argentina
  • Carlos Klein Dr. Klein Office, Province of Buenos Aires, Argentina
  • Emiliano Salmeri Argentine Society of Cardiology, Autonomous City of Buenos Aires, Argentina
  • Mercedes Carlini Argentine Society of Cardiology, Autonomous City of Buenos Aires, Argentina
  • Cecilia Araya Argentine Society of Cardiology, Autonomous City of Buenos Aires, Argentina
  • Diana Millán Argentine Society of Cardiology, Autonomous City of Buenos Aires, Argentina
  • Alberto Cafferata Argentine Society of Cardiology, Autonomous City of Buenos Aires, Argentina
  • Ezequiel Forte Argentine Society of Cardiology, Autonomous City of Buenos Aires, Argentina

DOI:

https://doi.org/10.47196/diab.v54i3Sup.369

Keywords:

treatments, healthyhabits, type 2 diabetes mellitus

Abstract

Introduction: patients (p) with type 2 diabetes mellitus (DM2) have an increased risk of presenting cardiovascular (CV) complications, which is also the main cause of death in this population. Certain lifestyle interventions and pharmacological treatments have shown a reduction in CV events, which is why they are among the first line of recommendations in the main treatment guidelines.

Objectives: evaluate adherence to a healthy lifestyle and the use of pharmacological treatments with cardiovascular benefit in a population of p with DM2. Observe if there are differences between p with and without cardiovascular disease (CVD).

Materials and methods: cross-sectional, observational and multicenter study. P attended in the cardiology office were consecutively recorded from May to July 2019. Of the total p evaluated with DM2, the first two of each day of care entered the study. A healthy lifestyle was defined as: 1) physical activity (physical activity >150 minutes/week); 2) normal waist circumference (WC) (<88 cm in women and <102 cm in men; 3) without obesity (BMI <30 kg/m2); 4) intake of >5 servings of fruits and vegetables/day; 5) non-smoking and pharmacological strategies with CV benefit. 1) use of statins; 2) use of iSGLT2 and ARGLP-1; 3) use of acetylsalicylic acid (ASA) in secondary prevention. Means, medians, and standard deviations were used as appropriate. T test to compare means and chi square or Fisher test for dichotomous variables.

Results: 649 p. 58.5% men and age 64.7 years (+/- 10.5). The baseline characteristics are seen in Table 1. In relation to healthy lifestyle habits, 42.4% were physically active, 91.2% were non-smokers, 21.5% had normal CP, 39.1% BMI <30 kg/ m2 and 49.9% consumed 5 or more servings of fruits and vegetables/day. Regarding pharmacological treatment, 70.4% received statins, 9.8% iSGLT2 and 3% ARGLP-1,
while the use of ASA in patients with CVD was 72.9%. In relation to the differences between the groups with or without CVD, those with CVD were less frequently smokers (93.2% CVD – 89.5% S/CVD p=0.034), they had a lower prevalence of obesity (BMI<30 kg /m2: 45.4% CVD vs 34.9% S/CVD p=0.002) and greater use of statins (81.4% C/CVD and 60.5% p=0.00001) and iSGLT2 (12.8 % ECV vs 7.1% S/ECV p=0.006), with no differences observed in the rest of the variables (Figure).

Conclusions: with the exception of smoking, we observed low adherence to healthy lifestyle measures and use of pharmacological treatments with cardiovascular benefit. Despite being a population with high CV risk, patients without CVD underused pharmacological treatments with CV benefit and the prevalence of obesity was higher than in patients with CVD.

Author Biographies

Augusto Lavalle Cobo, Argentine Society of Cardiology, Autonomous City of Buenos Aires, Argentina

Member of the Cardiometabolism Council

Paola Harwicz, Argentine Society of Cardiology, Autonomous City of Buenos Aires, Argentina

Member of the Cardiometabolism Council

Carlos Busso, Argentine Society of Cardiology, Autonomous City of Buenos Aires, Argentina

Member of the Cardiometabolism Council

Hugo Sanabria, Argentine Society of Cardiology, Autonomous City of Buenos Aires, Argentina

Cardiologist, specializing in diabetes; Member of the Cardiometabolism Council

Carolina Gómez Martín, CENDIA Diabetes Center, Concordia, Entre Ríos, Argentina

Medical specialist in Internal Medicine (University of Buenos Aires, UBA), specialized in Diabetes (Argentine Diabetes Society, SAD), Co-director of Cendia

Emiliano Salmeri, Argentine Society of Cardiology, Autonomous City of Buenos Aires, Argentina

Member of the Cardiometabolism Council

Mercedes Carlini, Argentine Society of Cardiology, Autonomous City of Buenos Aires, Argentina

Member of the Cardiometabolism Council

Cecilia Araya, Argentine Society of Cardiology, Autonomous City of Buenos Aires, Argentina

Member of the Cardiometabolism Council

Diana Millán, Argentine Society of Cardiology, Autonomous City of Buenos Aires, Argentina

Member of the Cardiometabolism Council

Alberto Cafferata, Argentine Society of Cardiology, Autonomous City of Buenos Aires, Argentina

Member of the Cardiometabolism Council

Ezequiel Forte, Argentine Society of Cardiology, Autonomous City of Buenos Aires, Argentina

Member of the Cardiometabolism Council

Published

2023-01-10

How to Cite

Lavalle Cobo, A., Harwicz, P., Busso, C., Napoli, J., Sanabria, H., Gómez Martín, C., Romano, A., Klein, C., Salmeri, E., Carlini, M., Araya, C., Millán, D., Cafferata, A., & Forte, E. (2023). O8 Use of therapeutic strategies with cardiovascular benefit in a population of patients with type 2 diabetes in follow up by cardiologist. Journal of the Argentine Society of Diabetes, 54(3Sup), 93–93. https://doi.org/10.47196/diab.v54i3Sup.369

Issue

Section

Selected articles. Oral presentations

Most read articles by the same author(s)

1 2 3 4 > >>